Results 91 to 100 of about 24,414 (214)
Potential of PCSK9 as a new target for the management of LDL cholesterol
Research Reports in Clinical Cardiology, 2015 Guiliana Mombelli, Samuela Castelnuovo, Chiara PavanelloCardiovascular Department, Dyslipidemia Center, Azienda Ospedaliera Niguarda Cà Granda, Milan, ItalyAbstract: A large proportion of patients at high risk for cardiovascular disease continue ...
Mombelli G, Castelnuovo S, Pavanello C
doaj
Experimental Physiology, EarlyView.Abstract Current literature on the metabolic effects of long‐distance hiking is limited to case studies with discrepant findings, and no prior studies have examined the role of diet in shaping these outcomes. In this study, we investigated changes in lipid profiles and dietary factors among 12 participants who completed the Colorado Trail.
Kiaya Johnston +3 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend A, Sarcopenic obesity is defined as the age‐related loss of skeletal muscle mass and function that often leads to the progression of comorbidities, such as Alzheimer's disease (AD). Though the exact link between the two diseases is unknown, alterations in brain‐derived neurotrophic factor (BDNF) may be a contributor.
Emily N. Copeland +4 more
wiley +1 more source
Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome
Scientific ReportsSepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level ...
Suzan Omar Mousa +4 more
doaj +1 more source
Journal of Lipid Research, 2012 Successful development of drugs against novel targets crucially depends on reliable identification of the activity of the target gene product in vivo and a clear demonstration of its specific functional role for disease development.
Elena Fattori +10 more
doaj +1 more source
Variant Prioritization by Pedigree‐Based Haplotyping
Genetic Epidemiology, Volume 50, Issue 3, April 2026.ABSTRACT Whole genome sequence (WGS) data provides opportunities for comprehensive evaluation of variants that may influence complex traits. However, prioritizing the large number of variants, particularly those in non‐coding regions, is a challenge.
Rafael A. Nafikov +8 more
wiley +1 more source
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP” [PDF]
Circulation, 2021 openaire +2 more sources
British Journal of Pharmacology, Volume 183, Issue 7, Page 1313-1340, April 2026.Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang +18 more
wiley +1 more source
Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines
Cell Reports MedicineProprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.1 and Zhang et al.2 in Cell Reports Medicine and Cell Reports ...
Amirhossein Sahebkar, Maciej Banach
doaj +1 more source
Cancer & Metabolism, 2018 Background PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers.
Dipti Athavale +5 more
doaj +1 more source